International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 3 , Pages 727-733 , 1 July 2010

Evaluating and Reporting Dysphagia in Trials of Chemoirradiation for Head-and-Neck Cancer

Presented in part at the 50th Annual meeting of the American Society of Radiation Oncology (ASTRO), Boston, September 21–25, 2008.

  • Iris Gluck, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • ,
  • Felix Y. Feng, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • ,
  • Teresa Lyden, M.A.

      Affiliations

    • Department of Speech Pathology, University of Michigan, Ann Arbor, MI
    • ,
  • Marc Haxer, M.A.

      Affiliations

    • Department of Speech Pathology, University of Michigan, Ann Arbor, MI
    • ,
  • Francis Worden, M.D.

      Affiliations

    • Department of Medicine, University of Michigan, Ann Arbor, MI
    • ,
  • Douglas B. Chepeha, M.D.

      Affiliations

    • Department of Otolaryngology-Head Neck Surgery, University of Michigan, Ann Arbor, MI
    • ,
  • Avraham Eisbruch, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • Corresponding Author InformationReprint requests to: Avraham Eisbruch, M.D., Department of Radiation Oncology, University of Michigan Hospital, 1500 E Med Ctr Dr, Ann Arbor MI 48109. Tel: (734) 936-9337; Fax: (734) 769-7030

Received 3 March 2009 ,Revised 28 May 2009 ,Accepted 28 May 2009.

References 

  1. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437–443
  2. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol. 2006;24:3933–3938
  3. Anderson SJ. Some thoughts on the reporting of adverse events in phase II cancer clinical trials. J Clin Oncol. 2006;24:3821–3822
  4. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99–14. J Clin Oncol. 2005;23:3008–3015
  5. Cmelak AJ, Li S, Goldwasser MA, et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol. 2007;25:3971–3977
  6. Cohen EE, Haraf DJ, List MA, et al. High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. J Clin Oncol. 2006;24:3438–3444
  7. Garden AS, Harris J, Vokes EE, et al. Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2004;22:2856–2864
  8. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003;9:5936–5943
  9. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in carcinoma of the head and neck. J Clin Oncol. 2000;18:1458–1464
  10. Kies MS, Haraf DJ, Rosen F, et al. Concomitant paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001;19:1961–1969
  11. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma. J Clin Oncol. 2002;20:3964–3971
  12. Psyrri A, Kwong M, DiStasio S, et al. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation in head and neck cancer. J Clin Oncol. 2004;22:3061–3069
  13. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer. J Clin Oncol. 2005;23:79–87
  14. Sunwoo JB, Herscher LL, Kroog GS, et al. Concurrent paclitaxel and radiation in head and neck cancer. J Clin Oncol. 2001;19:800–811
  15. Tsao AS, Garden AS, Kies MS, et al. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for head and neck cancer. J Clin Oncol. 2006;24:4163–4169
  16. Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for advanced head and neck cancer. J Clin Oncol. 2000;18:1652–1661
  17. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy for head and neck cancer. J Clin Oncol. 2003;21:320–326
  18. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with head and neck cancer. J Clin Oncol. 2003;21:92–98
  19. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–1952
  20. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  21. Bourhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer. J Clin Oncol. 2006;24:2873–2878
  22. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer. J Clin Oncol. 2005;23:1125–1135
  23. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–2086
  24. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944
  25. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098
  26. Fu KK, Pajak TF, Trotti A, et al. A RTOG phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck carcinomas. Int J Radiat Oncol Biol Phys. 2000;48:7–16
  27. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22:4665–4673
  28. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7. Lancet. 2003;362:933–940
  29. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy. Int J Radiat Oncol Biol Phys. 2001;50:1161–1171
  30. Eisbruch A. Dysphagia and aspiration following chemo-irradiation of head and neck cancer: major obstacles to intensification of therapy. Ann Oncol. 2004;15:363–364
  31. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007;25:4118–4126
  32. Rosenthal DI, Lewin JS, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol. 2006;24:2636–2643
  33. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al. Impact of late treatment-related toxicity on quality of life. J Clin Oncol. 2008;26:3770–3776
  34. Feng FYFY, Kim HMHM, Lyden THTH, et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: Early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys. 2007;68:1289–1298
  35. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after chemoradiation for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53:23–28
  36. Karnell MP, MacCracken E. A database information storage and reporting system for videofluorographic oropharyngeal swallowing evaluation. Am J Speech Language Pathol. 1994;8:54–60
  37. O'Neil KH, Purdy M, Falk J, et al. The Dysphagia Outcome and Severity Scale. Dysphagia. 1999;14:139–145
  38. Terrell JE, Nanavati KA, Esclamado RM, et al. Head and neck cancer-specific quality of life: Instrument validation. Arch Otolaryngol Head Neck Surg. 1997;123:1125–1132
  39. Hassan SJ, Weymuller EA. Jr. Assessment of quality of life in head and neck cancer. Head Neck. 1993;15:485–496
  40. Trotti A, Colevas AD, Setser A, et al. CTCAE: development of a comprehensive grading system. Semin Radiat Oncol. 2003;13:176–181
  41. Trotti A, Pajak TF, Gwede CK, et al. TAME: Development of a new method for summarising adverse events of cancer treatment by RTOG. Lancet Oncol. 2007;8:613–624
  42. Hollen PPJ, Gralla RRJ, Cox CC, et al. A dilemma in analysis: Issues in the serial measurement of quality of life. Lung Cancer. 1997;18:119–136
  43. Scott C. Statistical issues in studies of toxicity modifiers. Semin Radiat Oncol. 2002;12:91–96
  44. Wiklund I. Assessment of patient-reported outcomes in clinical trials. Fundamental Clin Pharmacol. 2004;18:351–363
  45. Mahoney MR, Sargent DJ, O'Connell MJ, et al. Dealing with a deluge of data: an assessment of adverse event data. J Clin Oncol. 2005;23:9275–9281
  46. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007;25:4096–4103
  47. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting. Lancet Oncol. 2006;7:903–909
  48. Jensen K, Bonde Jensen A, Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. Radiother Oncol. 2006;78:298–305
  49. Pauloski BR, Rademaker AW, Logemann JA, et al. Swallow function and perception of dysphagia in patients with head and neck cancer. Head Neck. 2002;24:555–565
  50. Meirovitz A, Murdoch-Kinch CA, Schipper M, et al. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of HN cancer. Int J Radiat Oncol Biol Phys. 2006;66:445–453
  51. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with radiotherapy alone or with cetuximab. J Clin Oncol. 2007;25:2191–2197
  52. Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and evolution of adverse reporting in oncology. J Clin Oncol. 2007;25:5121–5127

 Supported in part by NIH grant PO1 CA59827.

 Conflict of interest: none.

PII: S0360-3016(09)00832-3

doi: 10.1016/j.ijrobp.2009.05.049

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 3 , Pages 727-733 , 1 July 2010

Article Tools

* Image Usage & Resolution